Epoch Biodesign raises $12M in strategic funding round
WestTech London’s Epoch Biodesign – an AI-powered biotech with a mission to transform plastic waste – has closed a $12M strategic funding round, bringing total capital raised to over $50M.
The finance round – which includes investment from Lululemon, KOMPAS VC, Happiness Capital, Extantia and Leitmotif – will accelerate Epoch Biodesign’s commercialisation strategy across apparel, automotive and industrial markets.
The Grapht Works-based biotech and enzymatic recycling pioneer recently signed an MoU with INVISTA on its journey from multi-tonne to multi-kilotonne production, and construction is currently underway on the company’s demonstration nylon 6,6 biorecycling facility.
Circular production, built for scale
Epoch Biodesign’s process deconstructs end-of-life nylon materials back to their chemical building blocks, using AI-engineered enzymes. The resulting monomers are used to produce virgin-quality nylon 6,6 – without the need for petrochemical feedstock. Nylon 6,6 is a critical material used across some of the world’s most demanding industries – from automotive, electronics and textiles to medical devices and renewable energy.
